Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx cardiac safety in metastatic breast cancer
NCT00779285Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2006
- Primary completion
- Aug 2006
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
A Phase 4 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Merck & Co.. Started Feb 2006; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00779285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00779285.